Vaccine Reaction Clinical Trial
Official title:
Kinetics and Stability of Anti-SARS-CoV-2 Antibodies and Virus Neutralization After COVID-19 Vaccination in a Swiss Cohort
Analysis of SARS-CoV-2 antibodies and serum virus neutralisation in vaccinated heath care personnel. Analysis of virus neutralisation as a function of age, gender, and history of COVID-19 infection.
This study is an observational study with subsequent use of coded biological material. Sera of Universitiy Hospital of Zurich (USZ) personnel vaccinated with BNT162b2 (BioNTech/Pfizer) was analyzed for SARS-CoV-2 specific antibodies and virus neutralization. Serum was analysed for virus-specific IgG and IgA using ELISA kits from Euroimmun (Kriens, Switzerland) according to the manufacturer's instruction. IgG was determined with the quantitative Anti-SARS-CoV-2 Quantivac kit and IgA was determined with the semi-quantitative Anti-SARS-CoV-2 kit The kits determine antibodies against the spike-1 protein. The sera were not diluted and not heat-inactivated prior to testing. The developed 96-well plates were analysed by reading absorbance at 450 nm using an ELx808 ELISA reader from BioTek Instr. Inc. In addition, a SARS-CoV-2 neutralization assay was developed at the department. In this Tissue Culture Infection Dose (TCID) assay, Vero cells were infected with live SARS-CoV-2, and sera were added at various dilutions to test the potential to neutralize viral infection. The assay was conducted in a biosafety level 3 lab. Briefly, VERO-E6 cells were grown overnight to ca. 80-90% adherence in flat-bottom 96-well cell culture plates. The SARS-CoV-2 was then mixed in round-bottom 96 well titre plates with 2-fold serial dilutions of serum and incubated. The virus-serum mixture was then added to the VERO-E6 cell, and the cultures were incubated again. After three days, the cultures were fixed by addition of paraformaldehyde and stained with crystal violet for visualisation of cytotoxicity. The highest serum dilution preventing infections of the cells was defined as the neutralization titre. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06091410 -
Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines
|
Phase 4 | |
| Completed |
NCT05057910 -
SARS-CoV-2 (Covid-19) RBD Antibody in My Duc Hospital Healthcare Workers
|
||
| Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
| Recruiting |
NCT05028257 -
Allergy and COVID-19 Vaccines
|
Phase 3 | |
| Active, not recruiting |
NCT06286488 -
Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza
|
Phase 4 | |
| Recruiting |
NCT05546502 -
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
|
Phase 3 | |
| Completed |
NCT05869201 -
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine
|
Phase 2/Phase 3 | |
| Completed |
NCT04798677 -
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
|
N/A | |
| Recruiting |
NCT05598372 -
Infant Pain During Vaccination and Maternal Anxiety
|
N/A | |
| Active, not recruiting |
NCT06002503 -
Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection
|
Phase 1 | |
| Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
| Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
| Completed |
NCT03400878 -
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
|
Phase 4 | |
| Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
| Completed |
NCT05069714 -
One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.
|
Phase 3 | |
| Completed |
NCT04576910 -
Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China
|
Phase 4 | |
| Not yet recruiting |
NCT05094635 -
Immunogenicity Against SARS-CoV-2 in COVID-19 Close Contacts
|
||
| Recruiting |
NCT05493917 -
A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine
|
||
| Not yet recruiting |
NCT05171946 -
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
|
Phase 1 | |
| Completed |
NCT05154383 -
Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression
|
Phase 4 |